As per reports, Johnson & Johnson (JNJ) will be adding Chile and Peru to the Latin nations where it plans to conduct Phase III trials for its vaccine against COVID-19. The trial involves 60,000 volunteers from Brazil, Chile, Colombia, and Peru, coordinated by J&J’s pharmaceutical unit Janssen along with local centers and hosted by Miguel O’Ryan of the University of Chile’s School of Medicine. Chile is also in talks with CanSino, AstraZeneca Plc, and Moderna Inc for trials. Janssen and Chilean health ministry remained unavailable for comment.
“From our point of view, as soon as we have the vaccine available, within three weeks we should be able to vaccinate the first volunteer. We have been working to develop all the necessary strategy and infrastructure to carry out a large clinical trial.” stated Miguel O’Ryan.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.